• Delafloxacin comes in tablet form as well as in injection form.
• The tablet can be taken as a whole with sufficient quantity of water without crushing or chewing.
• Tablets can be taken with food to minimise gastric discomfort.
Injection reconstitution and dilution:
• Delafloxacin injection should be reconstituted and diluted under aseptic conditions. Each 300mg vial can be reconstituted with either 5% dextrose or 0.9% sodium chloride and should be completely shaken by dissolving.
• The reconstituted solution should be diluted into an intravenous bag to obtain a total volume of 250 ml either with a 5% dextrose or 0.9% sodium chloride to achieve a concentration of 1.2 mg/ml before administration.
• It is necessary to inspect for the presence of any visible particles or discoloration of the parenteral solution prior administration.
• The total infusion time should be over 60 minutes.
• The recommended adult dose of delafloxacin can be chosen from the below depending on the severity of the infection:
a) Delafloxacin injection of 300mg twice daily over 1 hour by intravenous infusion for a period of 5 to 14 days.
Or
b) Delafloxacin injection of 300mg twice daily over 60 minutes by intravenous infusion and then to switch to 450mg tablet orally twice a day for a total period of 5 to 14 days.
Or
c) Tablets of 450mg of delafloxacin to be taken orally twice daily for a period of 5 to 14 days.
Dose adjustment in patients with renal impairment:
• No dose adjustment is required in patients with an estimated glomerular filtration rate (eGFR) of 30-89 mL/min/1.73m2.
• In patients with an eGFR 15-29 mL/min/1.73m2, 200mg of delafloxacin injection can be given intravenously twice daily or the 200mg injection twice daily can be switched to 450 mg tablet orally twice a day to complete the course of the treatment.
• Delafloxacin injection and tablets are not recommended in patients with end-stage renal disease including hemodialysis patients.
• Allergy or known hypersensitivity to delafloxacin drug
• Viral infections such as common cold or flu
• Known history of myasthenia gravis
• Nerve disorders such as peripheral neuropathy
• Seizures or any existing head injury
• End-stage kidney disease
• Tendonitis or arthritis
• Children less than 18 years, during pregnancy and breastfeeding
• The tablet can be taken as a whole with sufficient quantity of water without crushing or chewing.
• Tablets can be taken with food to minimise gastric discomfort.
Injection reconstitution and dilution:
• Delafloxacin injection should be reconstituted and diluted under aseptic conditions. Each 300mg vial can be reconstituted with either 5% dextrose or 0.9% sodium chloride and should be completely shaken by dissolving.
• The reconstituted solution should be diluted into an intravenous bag to obtain a total volume of 250 ml either with a 5% dextrose or 0.9% sodium chloride to achieve a concentration of 1.2 mg/ml before administration.
• It is necessary to inspect for the presence of any visible particles or discoloration of the parenteral solution prior administration.
• The total infusion time should be over 60 minutes.
Dosage & When it is to be taken
Adult Dose:• The recommended adult dose of delafloxacin can be chosen from the below depending on the severity of the infection:
a) Delafloxacin injection of 300mg twice daily over 1 hour by intravenous infusion for a period of 5 to 14 days.
Or
b) Delafloxacin injection of 300mg twice daily over 60 minutes by intravenous infusion and then to switch to 450mg tablet orally twice a day for a total period of 5 to 14 days.
Or
c) Tablets of 450mg of delafloxacin to be taken orally twice daily for a period of 5 to 14 days.
Dose adjustment in patients with renal impairment:
• No dose adjustment is required in patients with an estimated glomerular filtration rate (eGFR) of 30-89 mL/min/1.73m2.
• In patients with an eGFR 15-29 mL/min/1.73m2, 200mg of delafloxacin injection can be given intravenously twice daily or the 200mg injection twice daily can be switched to 450 mg tablet orally twice a day to complete the course of the treatment.
• Delafloxacin injection and tablets are not recommended in patients with end-stage renal disease including hemodialysis patients.
When it is not to be taken (Contraindications)
Delafloxacin should not be used in patients with the following conditions-• Allergy or known hypersensitivity to delafloxacin drug
• Viral infections such as common cold or flu
• Known history of myasthenia gravis
• Nerve disorders such as peripheral neuropathy
• Seizures or any existing head injury
• End-stage kidney disease
• Tendonitis or arthritis
• Children less than 18 years, during pregnancy and breastfeeding
